OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Update

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 9,877 shares, a drop of 59.5% from the December 31st total of 24,394 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 70,169 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 70,169 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s shares are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in shares of OnKure Therapeutics in the 2nd quarter valued at approximately $25,000. Bailard Inc. purchased a new position in OnKure Therapeutics in the second quarter valued at $34,000. Rangeley Capital LLC acquired a new stake in OnKure Therapeutics in the second quarter valued at $71,000. GSA Capital Partners LLP raised its stake in OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock valued at $163,000 after buying an additional 37,459 shares in the last quarter. Finally, Prosight Management LP lifted its holdings in OnKure Therapeutics by 67.8% during the 3rd quarter. Prosight Management LP now owns 267,959 shares of the company’s stock worth $737,000 after buying an additional 108,267 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on OKUR. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded OnKure Therapeutics to a “sell” rating in a report on Saturday, November 1st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $32.00.

OnKure Therapeutics Price Performance

Shares of NASDAQ OKUR traded down $0.09 during mid-day trading on Friday, hitting $2.64. The company had a trading volume of 69,927 shares, compared to its average volume of 67,208. The company has a market capitalization of $35.77 million, a PE ratio of -0.55 and a beta of 0.47. The business’s 50-day simple moving average is $2.94 and its 200 day simple moving average is $2.78. OnKure Therapeutics has a 1-year low of $1.70 and a 1-year high of $6.48.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.11. On average, analysts expect that OnKure Therapeutics will post -4.05 EPS for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.